Statement Of Cash Flows [Abstract]

BerGenBio - Filing #5877180

Concept 2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for interest income
3,521,000 NOK
3,055,000 NOK
Adjustments for increase (decrease) in trade and other payables
14,564,000 NOK
31,809,000 NOK
Adjustments for depreciation expense
456,000 NOK
223,000 NOK
Cash flows from (used in) financing activities [abstract]
Payments for share issue costs
8,827,000 NOK
36,971,000 NOK

Talk to a Data Expert

Have a question? We'll get back to you promptly.